Skip to content
10-K

Annual Report

Reviva Pharmaceuticals Holdings, Inc. RVPH

0001437749-26-010126

← back to feed
Filed
Mar 30, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 27, 2026 12.81M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$24.59M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$33.54M
Short Term Debt FY 2025 · Dec 31, 2025 $406.88K
Short Term Debt FY 2025 · Dec 31, 2024 $458.15K
Cash And Equivalents FY 2025 · Dec 31, 2025 $14.44M
Cash And Equivalents FY 2025 · Dec 31, 2024 $13.48M
Stockholders Equity FY 2025 · Dec 31, 2025 $8.65M
Stockholders Equity FY 2025 · Dec 31, 2024 $812.57K
Stockholders Equity FY 2025 · Dec 31, 2023 $5.72M
Current Liabilities FY 2025 · Dec 31, 2025 $7.28M
Current Liabilities FY 2025 · Dec 31, 2024 $14.6M
Total Liabilities FY 2025 · Dec 31, 2025 $7.28M
Total Liabilities FY 2025 · Dec 31, 2024 $14.69M
Current Assets FY 2025 · Dec 31, 2025 $15.1M
Current Assets FY 2025 · Dec 31, 2024 $14.68M
Total Assets FY 2025 · Dec 31, 2025 $15.92M
Total Assets FY 2025 · Dec 31, 2024 $15.5M
Eps Basic FY 2025 · Dec 31, 2025 −$5.48
Eps Basic restated FY 2025 · Dec 31, 2024 −$17.73
Sga Expense FY 2025 · Dec 31, 2025 $8.49M
Sga Expense FY 2025 · Dec 31, 2024 $7.89M
Rd Expense FY 2025 · Dec 31, 2025 $11.71M
Rd Expense FY 2025 · Dec 31, 2024 $22.91M
Net Income FY 2025 · Dec 31, 2025 −$19.86M
Net Income FY 2025 · Dec 31, 2024 −$29.92M
Operating Income FY 2025 · Dec 31, 2025 −$20.2M
Operating Income FY 2025 · Dec 31, 2024 −$30.8M